Vycor Medical Stock Performance
| VYCO Stock | USD 0.07 0 1.45% |
On a scale of 0 to 100, Vycor Medical holds a performance score of 3. The entity has a beta of -1.02, which indicates a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Vycor Medical are expected to decrease slowly. On the other hand, during market turmoil, Vycor Medical is expected to outperform it slightly. Please check Vycor Medical's total risk alpha and the relationship between the potential upside and price action indicator , to make a quick decision on whether Vycor Medical's existing price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Vycor Medical are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady fundamental indicators, Vycor Medical displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 46 K | |
| Total Cashflows From Investing Activities | -38.4 K | |
| Free Cash Flow | -17 K |
Vycor |
Vycor Medical Relative Risk vs. Return Landscape
If you would invest 7.80 in Vycor Medical on September 30, 2024 and sell it today you would lose (0.80) from holding Vycor Medical or give up 10.26% of portfolio value over 90 days. Vycor Medical is currently generating 0.5802% in daily expected returns and assumes 12.0034% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Vycor, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vycor Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vycor Medical's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Vycor Medical, and traders can use it to determine the average amount a Vycor Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0483
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VYCO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.0 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Vycor Medical is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vycor Medical by adding it to a well-diversified portfolio.
Vycor Medical Fundamentals Growth
Vycor OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Vycor Medical, and Vycor Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vycor OTC Stock performance.
| Return On Asset | -0.24 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.31) % | |||
| Current Valuation | 4.17 M | |||
| Shares Outstanding | 32.53 M | |||
| Price To Earning | (2.74) X | |||
| Price To Sales | 2.60 X | |||
| Revenue | 1.39 M | |||
| EBITDA | (252.02 K) | |||
| Cash And Equivalents | 43.62 K | |||
| Total Debt | 150 K | |||
| Debt To Equity | 390.90 % | |||
| Book Value Per Share | (0.09) X | |||
| Cash Flow From Operations | 21.37 K | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 935.36 K | |||
| Retained Earnings | (24.68 M) | |||
| Current Asset | 559 K | |||
| Current Liabilities | 1.14 M | |||
About Vycor Medical Performance
By examining Vycor Medical's fundamental ratios, stakeholders can obtain critical insights into Vycor Medical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Vycor Medical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited. Vycor Medical operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 6 people.Things to note about Vycor Medical performance evaluation
Checking the ongoing alerts about Vycor Medical for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Vycor Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vycor Medical is way too risky over 90 days horizon | |
| Vycor Medical has some characteristics of a very speculative penny stock | |
| Vycor Medical appears to be risky and price may revert if volatility continues | |
| Vycor Medical has a very high chance of going through financial distress in the upcoming years | |
| Vycor Medical has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Vycor Medical currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 390.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vycor Medical has a current ratio of 0.15, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Vycor Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Vycor Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vycor Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vycor to invest in growth at high rates of return. When we think about Vycor Medical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.39 M. Net Loss for the year was (435.66 K) with profit before overhead, payroll, taxes, and interest of 1.26 M. | |
| About 65.0% of Vycor Medical outstanding shares are owned by insiders |
- Analyzing Vycor Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vycor Medical's stock is overvalued or undervalued compared to its peers.
- Examining Vycor Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vycor Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vycor Medical's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Vycor Medical's otc stock. These opinions can provide insight into Vycor Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Vycor OTC Stock
Vycor Medical financial ratios help investors to determine whether Vycor OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vycor with respect to the benefits of owning Vycor Medical security.